NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes.

Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, United States.
Pharmacological Research (Impact Factor: 3.98). 02/2011; 63(5):405-13. DOI: 10.1016/j.phrs.2011.01.013
Source: PubMed

ABSTRACT CYP2Cs and CYP3A4 sub families of enzymes of the Cytochrome P450 super family metabolize clinically prescribed therapeutics. Constitutive and induced expressions of these enzymes are under the control of HNF4α and rifampicin activated PXR. In the present study, we show a mechanism for ligand dependent synergistic cross talk between PXR and HNF4α. Two-hybrid screening identified NCOA6 as a HNF4α interacting protein. NCOA6 was also found to interact with PXR through the first LXXLL motif in GST pull down and mammalian two hybrid assays. NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4α in the presence of rifampicin. However silencing NCOA6 abrogated the synergistic activation and induction of CYP2C9 by PXR-HNF4α but not of CYP3A4. ChIP analysis revealed that NCOA6 could bridge HNF4α and PXR binding sites of the CYP2C9 promoter. Our results indicate that NCOA6 is responsible for the synergistic activation of CYP2C9 by HNF4α and PXR and NCOA6 differentially regulates CYP2C9 and CYP3A4 gene expression though both the genes are regulated by the same nuclear receptors.

Download full-text


Available from: Ritu Rana, Aug 20, 2015
  • Source
    • "They are found at highest levels in human liver (Goldstein and de Morais, 1994; Inoue et al., 1994; Klose et al., 1999; Nishimura et al., 2003), but CYP2C protein and/or mRNA expression has been detected at lower levels in extrahepatic tissues such as kidney, lung, heart, endothelial tissue, adrenal gland, mammary gland, and brain (McFayden et al., 1998; Klose et al., 1999; Nishimura et al., 2003; Yasar et al., 2003; Delozier et al., 2007; Deng et al., 2011). Numerous studies have described the transcriptional upregulation of CYP2C genes by xenobiotics (Pascussi et al., 2000a; Ferguson et al., 2002; Chen et al., 2004), including clinically prescribed and nonprescription drugs such as phenobarbital , rifampicin, St. John's wort, and dexamethasone, through the xenobiotic-sensing receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR), and glucocorticoid receptor (GR) (Ferguson et al., 2002; Chen et al., 2003a, 2004; Rana et al., 2010, 2011; Surapureddi et al., 2011). The CYP2C genes are also up-regulated by the liverenriched receptor hepatic nuclear factor 4␣ (HNF4␣) (Ferguson et al., 2005; Rana et al., 2010; Yue et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The CYP2C genes are extensively regulated at the transcriptional stage. The present study shows for the first time that CYP2Cs are also regulated post-transcriptionally by microRNAs (miRNAs). By using online search engines, we found potential miRNA response elements (MREs) in the 3'-untranslated region (3'-UTR) of the CYP2C mRNAs. Among these were a MRE for the miRNAs miR-103 and miR-107 in the 3'-UTR of human CYP2C8. CYP2C8 protein levels (measured through immunoblot analyses) did not correlate with CYP2C8 mRNA levels (measured through quantitative polymerase chain reaction analyses) in human liver samples. The translation efficiency (protein/mRNA ratio) for CYP2C8 was inversely correlated with the expression of miR-103 and miR-107. When three copies of the putative MRE from CYP2C8 were inserted downstream from a luciferase expression reporter, transfection with precursors for miR-103 or miR-107 decreased luciferase activity in primary hepatocytes, whereas transfection with antisense oligonucleotides (AsOs) for miR-103/miR-107 increased luciferase activity. As expected, there was no effect of the precursors or AsOs when three copies of the putative MRE were inserted in the reverse orientation. When precursors for miR-103/miR-107 were transfected into primary human hepatocytes, CYP2C8 protein levels were decreased, whereas AsOs increased CYP2C8 protein levels. Neither precursors nor AsOs affected CYP2C8 mRNA levels, which indicated that the effect was post-transcriptional. Putative MRE motifs were also found in the 3'-UTRs of CYP2C9 and CYP2C19, which suggested that the same miRNAs could regulate translation of other members of the CYP2C family, although to a lesser degree than CYP2C8. These results clearly show that CYP2Cs are regulated post-transcriptionally by miR-103 and miR-107.
    Molecular pharmacology 06/2012; 82(3):529-40. DOI:10.1124/mol.112.078386 · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cytochrome P450 2C9 (CYP2C9) metabolizes dehydroepiandrosterone-sulfate (DHEA-S), but in elderly people the amount of DHEA-S remaining after CYP2C9 metabolization may be insufficient for optimal health. A prediction model, molecular docking, and molecular dynamics were used to screen the Traditional Chinese Medicine (TCM) database to determine molecular compounds that may inhibit CYP2C9. The candidate compounds apocynoside(I), 4-methoxymagndialdehyde, and prunasin have higher Dock Scores, and prediction bioactivity than warfarin (the control drug). The interaction between 4-methoxymagndialdehyde and CYP2C9 is more intense than with other TCM compounds, but the simulation is longer. In these compounds, apocynoside(I) and prunasin have a greater number of pathways for their flexible structure, but these structures create weak interactions. These candidate compounds, which are known to have antioxidation and hypolipidemic functions that have an indirect effect on the aging process, can be extracted from traditional Chinese medicines. Thus, these candidate compounds may become CYP2C9 inhibitors and play an important role in providing optimal health in the elderly.
    Evidence-based Complementary and Alternative Medicine 05/2014; 2014:404505. DOI:10.1155/2014/404505 · 1.88 Impact Factor